MA51232A - Indane-amines utiles en tant qu'antagonistes de pd-l1 - Google Patents
Indane-amines utiles en tant qu'antagonistes de pd-l1Info
- Publication number
- MA51232A MA51232A MA051232A MA51232A MA51232A MA 51232 A MA51232 A MA 51232A MA 051232 A MA051232 A MA 051232A MA 51232 A MA51232 A MA 51232A MA 51232 A MA51232 A MA 51232A
- Authority
- MA
- Morocco
- Prior art keywords
- indane
- antagonists
- amines useful
- amines
- useful
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862633973P | 2018-02-22 | 2018-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51232A true MA51232A (fr) | 2020-10-07 |
Family
ID=67687901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051232A MA51232A (fr) | 2018-02-22 | 2019-02-21 | Indane-amines utiles en tant qu'antagonistes de pd-l1 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10568874B2 (fr) |
| EP (1) | EP3755311A4 (fr) |
| JP (1) | JP7387616B2 (fr) |
| MA (1) | MA51232A (fr) |
| WO (1) | WO2019165043A2 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7185532B2 (ja) | 2016-06-27 | 2022-12-07 | ケモセントリックス，インコーポレイティド | 免疫調節化合物 |
| AU2018306619B2 (en) | 2017-07-28 | 2022-06-02 | Chemocentryx, Inc. | Immunomodulator compounds |
| CN111225665B (zh) | 2017-08-08 | 2023-12-08 | 凯莫森特里克斯股份有限公司 | 大环免疫调节剂 |
| TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| EP3755311A4 (fr) * | 2018-02-22 | 2021-11-10 | ChemoCentryx, Inc. | Indane-amines utiles en tant qu'antagonistes de pd-l1 |
| CA3093130C (fr) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Inhibiteurs pd-1/pd-l1 |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| JP2022539830A (ja) | 2019-07-10 | 2022-09-13 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１阻害剤としてのインダン |
| PE20221764A1 (es) | 2019-10-16 | 2022-11-11 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5604294A (en) | 1991-09-05 | 1997-02-18 | Luly; Jay R. | Macrocyclic immunomodulators |
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| GB9604926D0 (en) | 1996-03-08 | 1996-05-08 | Sandoz Ltd | Organic compounds |
| JP4875978B2 (ja) * | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| CA2647819C (fr) | 2006-03-31 | 2012-12-11 | Novartis Ag | Derives phenylcyclohexyliques en tant qu'inhibiteurs de dgat1 |
| DE102006017175A1 (de) | 2006-04-12 | 2007-10-18 | Robert Bosch Gmbh | Balancierter Serienmischer für Hochfrequenzsignale |
| WO2008008059A1 (fr) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Agents anti-cancer et leurs utilisations |
| WO2008089307A2 (fr) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| KR102276644B1 (ko) | 2013-09-04 | 2021-07-13 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조절제로서 유용한 화합물 |
| RS57559B1 (sr) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Tech Ltd | 1,3,4-oksadiazol i 1,3,4-tiadiazol derivativi kao imunomodulatori |
| SG11201601682RA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | 1,2,4-oxadiazole derivatives as immunomodulators |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| WO2017025368A1 (fr) | 2015-08-07 | 2017-02-16 | Boehringer Ingelheim International Gmbh | Acides indanylaminopyridylcyclopropanecarboxyliques, compositions pharmaceutiques et leurs utilisations |
| NL1041468B1 (en) | 2015-09-08 | 2017-03-22 | Bosch Gmbh Robert | Metal ring component of a drive belt for a continuously variable transmisson. |
| EP3347358B1 (fr) | 2015-09-09 | 2019-11-27 | Boehringer Ingelheim International GmbH | Acides [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acétiques, compositions pharmaceutiques et utilisations associées |
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| EP3365340B1 (fr) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Composés hétérocycliques utilisés comme immunomodulateurs |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| EP3390361B1 (fr) | 2015-12-17 | 2022-03-16 | Incyte Corporation | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| SG11201805300QA (en) | 2015-12-22 | 2018-07-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| EP3190103A1 (fr) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibiteurs de l'interaction protéine/protéine pd-1/pd-l1 |
| WO2017176965A1 (fr) | 2016-04-07 | 2017-10-12 | Chemocentryx, Inc. | Réduction de la charge tumorale par l'administration d'antagonistes de ccr1 en association avec des inhibiteurs de pd-1 ou des inhibiteurs de pd-l1 |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3466944B1 (fr) | 2016-05-23 | 2022-06-15 | Institute of Materia Medica, Chinese Academy of Medical Sciences | Dérivé d'éther d'alcool nicotinylique, procédé de préparation associé, composition pharmaceutique et ses utilisations |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3028685A1 (fr) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Composes heterocycliques utilises comme immunomodulateurs |
| JP7185532B2 (ja) | 2016-06-27 | 2022-12-07 | ケモセントリックス，インコーポレイティド | 免疫調節化合物 |
| CA3029857C (fr) | 2016-07-05 | 2023-07-04 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd | Compose d'acetylene aromatique ou d'ethylene aromatique, produit intermediaire, procede de preparation, composition pharmaceutique et leur utilisation |
| US10590105B2 (en) | 2016-07-08 | 2020-03-17 | Bristol-Meyers Squibb Company | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators |
| US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| WO2018045142A1 (fr) | 2016-09-02 | 2018-03-08 | Polaris Pharmaceuticals, Inc. | Inhibiteurs de points de contrôle de l'immunité, compositions et méthodes associées |
| US10771492B2 (en) | 2016-09-22 | 2020-09-08 | Microsoft Technology Licensing, Llc | Enterprise graph method of threat detection |
| WO2018118848A1 (fr) | 2016-12-20 | 2018-06-28 | Bristol-Myers Squibb Company | Composés utiles en tant qu'immunomodulateurs |
| CA3047991A1 (fr) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Composes heteroaromatiques bicycliques utilises en tant qu'immunomodulateurs |
| US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2934230T3 (es) | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
| HRP20221216T1 (hr) | 2016-12-22 | 2022-12-23 | Incyte Corporation | Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1 |
| WO2018119263A1 (fr) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Composés hétérocycliques utilisés en tant qu'inducteurs de l'internalisation de pd-l1 |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018121560A1 (fr) | 2016-12-29 | 2018-07-05 | 深圳微芯生物科技有限责任公司 | Composé d'urée, son procédé de préparation et son application |
| CN108395443B (zh) | 2017-02-04 | 2021-05-04 | 广州丹康医药生物有限公司 | 抑制程序性死亡受体配体1的环状化合物及其用途 |
| WO2018183171A1 (fr) | 2017-03-27 | 2018-10-04 | Bristol-Myers Squibb Company | Dérivés d'isoquinoléine substitués utilisés en tant qu'immunomutateurs |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2018196768A1 (fr) | 2017-04-26 | 2018-11-01 | 南京圣和药业股份有限公司 | Composé hétérocyclique servant d'inhibiteur de pd-l1 |
| CN108863963B (zh) | 2017-05-08 | 2022-05-27 | 南京圣和药物研发有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
| AU2018306619B2 (en) | 2017-07-28 | 2022-06-02 | Chemocentryx, Inc. | Immunomodulator compounds |
| CN111225665B (zh) | 2017-08-08 | 2023-12-08 | 凯莫森特里克斯股份有限公司 | 大环免疫调节剂 |
| EP3669872A4 (fr) | 2017-08-18 | 2021-05-05 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Composé ayant une activité inhibitrice de pd-l1, sa méthode de préparation et son utilisation |
| CN111712242B (zh) | 2017-09-25 | 2023-11-24 | 凯莫森特里克斯股份有限公司 | 使用趋化因子受体2(ccr2)拮抗剂和pd-1/pd-l1抑制剂的联合治疗 |
| EP3692053A1 (fr) | 2017-10-03 | 2020-08-12 | Bristol-Myers Squibb Company | Immunomodulateurs |
| CN109665968B (zh) | 2017-10-16 | 2022-02-22 | 四川科伦博泰生物医药股份有限公司 | 并环化合物及其制备方法和用途 |
| CN109678796B (zh) | 2017-10-19 | 2023-01-10 | 上海长森药业有限公司 | Pd-1/pd-l1小分子抑制剂及其制备方法和用途 |
| CN109721527B (zh) | 2017-10-27 | 2024-03-12 | 广州丹康医药生物有限公司 | 一种新型抗pd-l1化合物、其应用及含其的组合物 |
| CN111386265A (zh) | 2017-11-06 | 2020-07-07 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物 |
| CN109956898B (zh) | 2017-12-22 | 2021-03-26 | 上海海雁医药科技有限公司 | 免疫调节剂及其制法与医药上的用途 |
| US11384048B2 (en) | 2017-12-29 | 2022-07-12 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application |
| JP7214752B2 (ja) | 2018-01-23 | 2023-01-30 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤として有用な２，８－ジアシル－２，８－ジアザスピロ［５．５］ウンデカン化合物 |
| CN111448189A (zh) | 2018-02-05 | 2020-07-24 | 上海和誉生物医药科技有限公司 | 一种联芳基衍生物、其制备方法和在药学上的应用 |
| TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| EP3755311A4 (fr) * | 2018-02-22 | 2021-11-10 | ChemoCentryx, Inc. | Indane-amines utiles en tant qu'antagonistes de pd-l1 |
| JP7326306B2 (ja) | 2018-03-01 | 2023-08-15 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤として有用な化合物 |
| WO2019174533A1 (fr) | 2018-03-13 | 2019-09-19 | 广东东阳光药业有限公司 | Inhibiteur de pd-1/pd-l1 à petites molécules et son utilisation dans des médicaments |
| BR112020018610A2 (pt) | 2018-03-13 | 2020-12-29 | Jubilant Prodel LLC | Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas |
| FI3774791T3 (fi) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
| US20210040118A1 (en) | 2018-04-03 | 2021-02-11 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| CA3093130C (fr) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Inhibiteurs pd-1/pd-l1 |
| CN112752756A (zh) | 2018-05-11 | 2021-05-04 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| WO2020011209A1 (fr) | 2018-07-11 | 2020-01-16 | 上海和誉生物医药科技有限公司 | Agent immunosuppresseur, son procédé de préparation et son utilisation pharmaceutique |
| US20220119411A1 (en) | 2018-07-12 | 2022-04-21 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2020015717A1 (fr) | 2018-07-19 | 2020-01-23 | Betta Pharmaceuticals Co., Ltd | Immunomodulateurs, compositions et procédés associés |
| CN112566900B (zh) | 2018-07-19 | 2024-04-26 | 贝达药业股份有限公司 | 免疫调节剂及其组合物和制备方法 |
| US20210347785A1 (en) | 2018-08-01 | 2021-11-11 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Preparation and application of aromatic compound having immunoregulatory function |
| US20210236476A1 (en) | 2018-08-29 | 2021-08-05 | Chemocentryx, Inc. | Methods of treating cancer with small molecule pd-l1 inhibitors |
| CN109336857A (zh) | 2018-11-13 | 2019-02-15 | 南方医科大学 | 一种含取代联苯的黄酮及其应用 |
| CN109438263A (zh) | 2018-11-28 | 2019-03-08 | 南方医科大学 | 一种含取代联苯的萘及其应用 |
| CN109503546A (zh) | 2019-01-10 | 2019-03-22 | 南方医科大学 | 一种间苯二酚二苯甲醚及其应用 |
| CN109776377B (zh) | 2019-02-01 | 2021-08-24 | 沈阳药科大学 | 吲哚啉类化合物及其制备方法和应用 |
| CN109776445B (zh) | 2019-03-28 | 2022-12-06 | 中国药科大学 | 苯并噁二唑类化合物及其制备方法和医药用途 |
| SG11202112310TA (en) | 2019-05-15 | 2021-12-30 | Chemocentryx Inc | Triaryl compounds for treatment of pd-l1 diseases |
| CN110200959A (zh) | 2019-05-30 | 2019-09-06 | 天津科技大学 | 一种黄酮类化合物的应用 |
| CN110128415B (zh) | 2019-05-31 | 2022-03-25 | 沈阳药科大学 | 用作免疫调节剂的吲哚啉类化合物及其制备方法 |
| JP2022536845A (ja) | 2019-06-20 | 2022-08-19 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患の治療のための化合物 |
| JP2022539830A (ja) | 2019-07-10 | 2022-09-13 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１阻害剤としてのインダン |
| US11713307B2 (en) | 2019-10-16 | 2023-08-01 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
| PE20221764A1 (es) | 2019-10-16 | 2022-11-11 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 |
| CN116472045A (zh) | 2020-06-23 | 2023-07-21 | 坎莫森特里克斯公司 | 使用杂芳基联苯基酰胺衍生物治疗癌症的方法 |
-
2019
- 2019-02-21 EP EP19757004.7A patent/EP3755311A4/fr active Pending
- 2019-02-21 WO PCT/US2019/018919 patent/WO2019165043A2/fr unknown
- 2019-02-21 US US16/281,448 patent/US10568874B2/en active Active
- 2019-02-21 JP JP2020544264A patent/JP7387616B2/ja active Active
- 2019-02-21 MA MA051232A patent/MA51232A/fr unknown
-
2020
- 2020-01-14 US US16/742,104 patent/US11135210B2/en active Active
-
2021
- 2021-08-30 US US17/460,716 patent/US11759458B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11135210B2 (en) | 2021-10-05 |
| JP7387616B2 (ja) | 2023-11-28 |
| EP3755311A4 (fr) | 2021-11-10 |
| US20220175746A1 (en) | 2022-06-09 |
| US20200375962A1 (en) | 2020-12-03 |
| US20190282555A1 (en) | 2019-09-19 |
| WO2019165043A2 (fr) | 2019-08-29 |
| EP3755311A2 (fr) | 2020-12-30 |
| JP2021513996A (ja) | 2021-06-03 |
| WO2019165043A3 (fr) | 2020-04-30 |
| US11759458B2 (en) | 2023-09-19 |
| US10568874B2 (en) | 2020-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51232A (fr) | Indane-amines utiles en tant qu'antagonistes de pd-l1 | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA54546A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA54547A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA54076A (fr) | 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8 | |
| MA46745A (fr) | Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v | |
| MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
| MA46196A (fr) | Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| MA45377A (fr) | Composés hétérocycliques en tant qu'agents antibacteriens | |
| MA49563A (fr) | Anticorps bispécifiques en tant qu'inhibiteurs de points de contrôle | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA42990A (fr) | Composés utiles en tant qu'immunomodulateurs | |
| MA48765A (fr) | Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub | |
| MA45153A (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
| MA43862A (fr) | Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock | |
| MA52063A (fr) | Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique | |
| MA53377A (fr) | Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2 | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| MA52123A (fr) | Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 |